Previous studies have shown that compared to single-agent PD-1/PD-L1 inhibitor therapy, the combination of multiple immune checkpoint receptor antibodies, such as LAG-3 inhibitors [48], TIGIT inhibitors [49], etc., significantly improved anti-tumour efficacy. Here, CD274 is linked to neoplasm.